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3 
INTRODUCTION 
 
Definition of Asthma 
Asthma is heterogeneous disease, usually characterized by chronic airway inflammation. It 
is defined by history of respiratory symptoms such as wheeze, shortness of breath, chest 
tightness, and cough that vary over time and intensity, together with variable expiratory 
airflow limitation (1). 
Asthma is a common, chronic respiratory disease affecting 1-18% of the population in 
different contries; this pathology is characterized by variable simptoms and by variable 
expiratory airflow limitation. Both symptoms and airflow limitation characteristically vary 
over time and in intensity. 
These variations are often triggered by factors such as exercize, allergen or irritant, change 
in weather, or viral respiratory infections (1). 
Asthma is a heterogeneous disease, with different underlying disease processes. 
Recognizable clusters of demographic, clinical and/or pathophysiological characteristics 
are often called “asthma phenotypes”. In patients with more severe asthma, some 
phenotype-guided treatments are available. 
More research is needed to understand the clinical utility of phenotypic classification in 
asthma. 
Many phenotypes have been identified. Some of the most common included: 
allergic asthma, non-allergic asthma, late-onset asthma, asthma with fixed airflow 
limitation, asthma with obesity (1). 
Other characteristics of asthma are an exaggerated responsiveness of the airways to various 
stimuli, and in most cases, a specific type of chronic inflammation of the airways 
characterized by an increased number of CD4
+
 Th2 lymphocytes, eosinophils and 
methacromatic cells in the airway mucosa, and increased thickness of the reticular layer of 
the epithelial basement membrane, and increased volume of airway smooth muscle (1-3) 
(Figure 1). 
Familial predisposition, atopy, and exposure to allergens and occupational sensitising 
agents are important risk factors for asthma, even though the causes of asthma—the factors 
responsible for the development of asthma rather than its exacerbations—remain largely 
undetermined (1). 
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Minimum requirements for the diagnosis of asthma  
The diagnosis of asthma is based on an appropriate clinical history, together with the 
demonstration of variable and/or reversible airflow limitation, using lung function tests, 
particularly peak expiratory flow (PEF) or spirometry. Allergy tests are also often 
performed during the initial assessment of a patient with suspected asthma, to identify 
possible triggers of asthma and to guide their avoidance (1, 2).  
Asthma clusters in families, and its genetic determinants appear to be linked to those of 
other allergic IgE-mediated diseases. Thus, a personal or family history of asthma and/or 
allergic rhinitis, atopic dermatitis, or eczema increases the likelihood of a diagnosis of 
asthma. 
 
Symptoms and medical history 
Patients with asthma seek medical attention because of respiratory symptoms. A typical 
feature of asthma symptoms is their variability. One or more of the following symptoms—
wheezing, chest tightness, episodic shortness of breath and/or cough are reported by more 
than 90% of patients with asthma (1, 2). However, the presence of these symptoms is not 
diagnostic, because similar symptoms can be present with other respiratory or even cardiac 
diseases, or may be triggered by different stimuli in non-asthmatics, e.g. by acute viral 
infections. In some asthmatics, wheezing and chest tightness are absent, and the only 
symptom the patient complains of is chronic cough (“cough-variant asthma”). 
Symptoms of asthma may be triggered or worsened by several factors, such as exercise, 
exposure to allergens, viral infections, and emotions. Recurrent exacerbations of 
respiratory symptoms, worsening of lung function requiring change of treatment, 
unscheduled requests for medical assistance, and sometimes hospitalization are also among 
the characteristic clinical features of asthma. 
Physical activity is an important cause of symptoms for most asthma patients, particularly 
in children, and for some it is the only cause. Exercise-induced bronchoconstriction usually 
develops not during exercise, but 5 -10 minutes afterward, and it resolves spontaneously 
within 30-45 minutes. Prompt relief of symptoms after the use of inhaled β2 -agonist, or 
their prevention by pre-treatment with an inhaled β2 -agonist before exercise, supports a 
diagnosis of asthma. 
Important aspects of personal history are exposure to agents known to worsen asthma in 
the home, such as dusty environments, forced air heating system, or exposure to allergens 
(e.g. pets or house dust mites, cockroaches) to which the patient is sensitized; workplace 
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conditions, environmental tobacco smoke, or even the general environment (e.g., diesel 
fumes in traffic).  
Since respiratory symptoms of asthma are non-specific, the differential diagnosis is quite 
extensive, and the main goal for the physician is to consider and exclude other possible 
diagnoses (Table 1). This is even more important if the response to a trial of therapy has 
been negative. 
While respiratory symptoms suggest asthma, the sine qua non condition for the objective 
diagnosis of asthma is the presence of reversible airflow obstruction in patients who have 
persistent airways obstruction, or airway hyperresponsiveness or increased PEF variability 
in subjects presenting without airways obstruction (1,2). 
 
Physical examination 
Physical examination in patients with asthma is often normal.  
The most frequent abnormality is respiratory wheezing (rhonchi) on auscultation, but it is 
may be absent or only heard on forced expiration (1). 
Typical physical signs of asthma attacks are wheezing on auscultation, cough, expiratory 
rhonchi throughout the chest, and signs of acute hyperinflation (e.g., poor diaphragmatic 
excursion at percussion, use of accessory muscles of respiration). Some patients, 
particularly children, may present with a predominant non-productive cough. In some 
asthmatics, wheezing—which usually reflects airflow limitation—may be absent or 
detectable only on forced expiration, even in the presence of significant airflow limitation; 
this may be due to hyperinflation or to very marked airflow obstruction. In these patients, 
however, the severity of asthma is mostly indicated by other signs, such as cyanosis, 
drowsiness, difficulty in speaking, tachycardia, hyperinflated chest, use of accessory 
muscles, and intercostal recession. 
 
Lung Function Tests  
Spirometry 
Lung function tests play a crucial role in the diagnosis and follow-up of patients with 
asthma. Spirometric measurements, the forced expired volume in 1 second (FEV1) and 
slow vital capacity (VC) or forced vital capacity (FVC), are the standard means for 
assessing airflow limitation. Spirometry is recommended at the time of diagnosis and for 
the assessment of the severity of asthma. It should be repeated to monitor the disease and 
when there is a need for reassessment, such as during exacerbations. 
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Poorly or non-reversible airflow limitation is usually defined by the absolute reduction of 
post-bronchodilator FEV1/FVC ratio <0.7. However, because this parameter varies with 
aging, it should be confirmed by post-bronchodilator FEV1/VC values below the lower 
limit of normal particularly in younger subjects. Measurements of residual volume and 
total lung capacity may be useful in assessing the degree of hyperinflation and/or 
enlargement of airspaces. Lung volumes may help in the differential diagnosis with COPD, 
but are not necessary for the diagnosis or for assessment of severity of asthma (1,3). In 
asthma, airflow limitation is usually reversible, either spontaneously or after treatment, 
except for moderate/severe asthma with fixed airway obstruction.. 
 
Peak expiratory flow 
An important tool for the diagnosis and subsequent treatment of asthma is the PEF meter. 
If spirometry does not reveal airflow limitation, then home monitoring of PEF for 2-4 
weeks may help to detect an increased variability of airway calibre, and assist in making 
the diagnosis of asthma. Daily monitoring of PEF (at least in the morning at awakening 
and in the evening hours, preferably after bronchodilator inhalation) is also useful to assess 
the severity of asthma and its response to treatment, and it can help patients to detect early 
signs of asthma deterioration. Diurnal variability is calculated as follows:  
PEFmax – PEFmin x 100 
PEFmax + PEFmin/2 
 
A diurnal variability of PEF of more than 20% is diagnostic of asthma, and the magnitude 
of the variability is broadly proportional to disease severity. PEF monitoring may be of use 
not only in establishing a diagnosis of asthma and assessing its severity but also in 
uncovering an occupational cause for asthma. When used in this way, PEF should be 
measured more frequently than twice daily and special attention should be paid to changes 
occurring in and out of the workplace.  
 
Reversibility to bronchodilators 
Clinical and/or functional reversibility on repeated testing is required for the diagnosis of 
asthma. Thus, even a single reversibility test (defined as > 12% reversibility and/or > 200 
mL in FEV1 after bronchodilator) can establish the diagnosis (1, 3). However, reversibility 
is often not present at the time of examination, particularly in patients on treatment, and 
thus the absence of reversibility does not exclude the diagnosis. Repeated testing of 
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reversibility of both clinical features and functional abnormalities may be useful in 
obtaining the best level of asthma control achievable and/or the best lung function for 
individual patients Achieving and maintaining lung function at the best possible level is 
one of the objectives of both asthma management.  
 
Airway Hyperresponsiveness 
In patients who have symptoms consistent with asthma but have normal lung function, 
bronchial provocation tests with methacholine, histamine or exercise are helpful in 
measuring airway hyperresponsiveness and thereby confirming or excluding the diagnosis 
of current asthma. These measurements are very sensitive, but poorly specific for a 
diagnosis of asthma. This means that while a negative test can be used to exclude a 
diagnosis of active asthma, a positive test does not always mean that a patient has asthma. 
While the measurement of airway hyperresponsiveness may be useful to confirm asthma in 
subjects with normal baseline lung function, it is not useful in presence of irreversible 
airflow limitation, and thus in the differential diagnosis between asthma and COPD (1, 3). 
 
Arterial Blood Gases 
In severe asthma and, more important, during acute exacerbations of asthma, the 
measurement of arterial blood gases while the patient is breathing air and/or after oxygen 
administration is essential for the diagnosis of respiratory failure. This test should be 
performed in all patients with clinical signs of acute or chronic respiratory and/or heart 
failure, and in patients with an acute asthma exacerbation and PEF <50%, patients who do 
not respond to treatment and those with a SaO2 ≤ 92% (1, 4).  
 
Allergy tests 
The presence of allergic disorders in a patient’s family history should be investigated in all 
patients with symptoms of asthma. A history provides important information about the 
patient’s lifestyle and occupation, both of which influence exposure to allergens and the 
time and factors possibly involved in onset and in exacerbations of asthma. Skin tests with 
all relevant allergens present in the geographic area, in which the patient lives, are the 
primary diagnostic tool in determining allergic status. Measurement of specific IgE is not 
usually more informative than a skin test, and is more expensive. Measurement of total IgE 
in serum has no value as a diagnostic test for atopy. The main limitation of methods to 
assess allergic status is that a positive test does not necessarily mean that the disease is 
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allergic in nature or that it is causing asthma, as some individuals have specific IgE 
antibodies without any symptoms and it may not be causally involved. The relevant 
exposure and its relation to symptoms must be confirmed by patient history (1, 2). 
 
Exhled nitric oxide 
The fractional concentration of exhaled nitric oxide (FENO) can be measured in some 
centers. FENO is increased in eosinophilic asthma but also in non-asthma contions 
(eosinophilic bronchitis, atopy and allergic rhinitis) and has not been estabilished has been 
usuful for making a diagnosis of asthma. Feno is decreased in smokers and during 
bronchoconstriction, and maybe increased or decreased during viral respiratory infections 
in patients (mainly non-smokers) with non-specific respiratory simptoms, a finding of 
FENO> 50 parts of billion (PPB) was associated with a good short-term response to ICS. 
However, there are no long term studies examining the safety of withholding ICS in 
patients with low initial FENO. Consequently, FENO cannot be raccomanded at present 
for deciding wheter treat patients with possible asthma with ICS (1). 
 
Additional tests 
While the diagnosis and assessment of severity of asthma can be fully established on the 
basis of clinical history and lung function tests additional tests are sometimes helpful to 
better characterize individual patients.  
 
Imaging 
While chest radiography may be useful to exclude diseases that may mimic asthma, it is 
not required in the confirmation of the diagnosis and management of asthma. The utility of 
chest radiography is to exclude other conditions that may imitate or complicate asthma, 
particularly acute asthma. Examples include pneumonia, cardiogenic pulmonary oedema, 
pulmonary thromboembolism, tumours (especially those that result in airway obstruction 
with resulting peripheral atelectasis), and pneumothorax.  
 
Assessment of Airway Inflammation 
While airway biopsies and bronchoalveolar lavage may provide useful information in 
research protocols, they are considered too invasive for the diagnosis or staging of asthma. 
In contrast, non-invasive markers of airway inflammation have been increasingly used in 
research protocols, particularly to differentiate asthma from COPD and measure response 
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to treatment. These non-invasive measurements include induced sputum and exhaled nitric 
oxide (FeNO). Induced sputum is not helpful in the diagnosis of asthma, but can be very 
useful in the management of severe asthma. In particular, induced sputum helps identify 
the persistence of airway eosinophilia or airway neutrophilia in patients with difficult-to-
treat asthma, which can be useful in deciding appropriate doses of inhaled corticosteroids 
and in reducing the risks of severe asthma exacerbations (5-7). FeNO is increased in 
atopic asthma, but less so in nonatopic asthma. Again it is not useful in the diagnosis, but 
can be helpful in monitoring adherence to inhaled corticosteroids, as it is effectively 
reduced by inhaled corticosteroids, but not by bronchodilators (5-7). 
 
Assessing asthma symptom control 
Directed questioning is important, as the frequency or severity of symptoms that patients 
regard as unacceptable or bothersome may vary for current raccomandations about the 
goals of asthma treatment and differs from patient to patient. To assess symptom control 
ask about the following in the past four weeks: frequency of asthma symtoms (days per 
week), any night waking due to asthma or limitation of activity, and frequency of reliever 
use for relief of symptoms. In general, due not include reliever taken before exercize, since 
this is often routine. 
There are asthma symptom control tools for adults and adolescent; these can be used in 
primary care to quickly identify patients who needs more detailed for patients: Asthma 
Control Questionnaire, Asthma Control Test; when different system used for assessing 
asthma symptom control, the results correlate broadly with each other, but are not 
identical. Respiratory symptoms maybe non-specific so, when assessing changes in 
symptom control, it is important to clarify that symptoms are due to asthma. 
The second component of assessing asthma control is to identify whether the patient is at 
risk of adverse asthma, particularly exacerbations, fixed airflow limitation, and side-effects 
of medications. Asthma symptom although an important outcome for patients, and 
themselves a strong predictor of future risk of exacerbations. 
 
Management and treatment 
Considering its chronic nature and life-long duration, asthma can be effectively managed 
only by developing a partnership between the patient and his or her doctor or health-
professional, that may provide the tools for a guided self-management possibly written 
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plan including self-monitoring, and periodically review of treatment and level of asthma 
control. Education plays a major role in this partnership (1).  
 
Long term pharmacologic treatment 
The main of asthma pharmacologic treatment is to achieve and maintain current control of 
day-to-day symptoms, as well as preventing of the future risk of severe asthma 
exacerbations, while using the safest treatment algorithm (1). While the initial treatment 
should be started according to the degree of asthma control at the first visit, subsequently 
treatment should be adjusted according to the level of asthma control achieved (1, 9-11). 
Usually regular treatment is lowered only after a significant period of acceptable asthma 
control (e.g. not less than 3 months). This means that monitoring of asthma is essential to 
maintain asthma control and to establish the minimal treatment requirements. Step-up and 
step-down of treatment is not standardized, and thus should be tailored to the individual 
patient to achieve and maintain control with the minimum amount of medication.  
Medications to treat asthma can be classified as controllers or relievers. Medications are 
preferably administered by inhalation, as this approach is the most effective way to treat 
asthma and has the fewest side effects. Controller medications (inhaled corticosteroids 
alone or in combination with long acting β2-agonists) are taken daily on a long-term basis 
to keep asthma under clinical control. In asthma, long acting β2-agonists should be used 
only in combination with inhaled corticosteroids when the latter are insufficient to achieve 
control, and should be discontinued only when control is maintained. 
Only in patients not controlled by optimal doses of inhaled corticosteroids combined with 
long acting beta2-agonists, should other secondary agents may be considered. These 
include anti-leukotrienes, theophylline, systemic corticosteroids, or anti-IgE monoclonal 
antibodies in very specific cases. 
Reliever medications (predominantly rapid acting β2-agonists) are medications used on an 
as-needed basis that act quickly to reverse bronchoconstriction and relieve asthma 
symptoms. Ideally, if patients are adequately controlled, they should rarely need rescue 
medications. The use of a combination of a inhaled rapid acting β2-agonists and 
corticosteroid both as controller and reliever is effective in maintaining high levels of 
asthma control (9-11).  
Smoking asthmatics are resistant to antiasthma medications and should be primarily treated 
for smoking addition (12). Asthmatic smokers may develop features of COPD (1, 3, 12)..  
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Specific immunotherapy in asthma is limited as 1) it requires the identification of a single 
clinically relevant allergen, 2) can be use safely only in mild asthmatics that are usually 
well controlled by environmental interventions or pharmacotherapy, and 3) maybe 
associated to adverse events (1, 2).  
 
Treatment of exacerbations 
Shortness of breath, cough, wheezing, and/or chest tightness, may develop or worsen in 
subject with asthma even when they are under regular treatment (1, 4). Milder 
exacerbations are usually managed by the patients with an increased as needed use of rapid 
acting β2-agonists alone or in combination in combination with inhaled steroids. More 
severe exacerbations, or exacerbations that do not respond to the increased use of rescue 
medications, require repetitive administration of rescue medication and systemic, 
preferably oral, corticosteroids, and in the very severe cases with oxygen supplementation. 
Severe exacerbations require medical attention or and in some instances hospital 
admission.  
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STUDY  
 
The 2014 revision of the Global Initiative for Asthma (GINA) guidelines recommends first 
assessing the level of asthma control and then planning treatment accordingly.
1
 For 
patients not controlled by low-dose inhaled corticosteroid (ICS), guidelines recommend a 
combination of low-dose ICS and a long-acting β2-agonist (LABA) plus a rapid-acting β2-
agonist for symptom relief, or inhaled ICS/rapid-acting LABA combination both regular 
and for symptom relief. This approach, called same maintenance and reliever therapy 
(SMART), achieves similar asthma control but more effective reduction of exacerbations 
in moderate to severe asthmatics (13-21). 
Recent studies have undermined the axiom that treatment with ICS must be regular to 
achieve and maintain asthma control, as equivalent control has been obtained either with 
prn use of an inhaled combination of a short acting beta2 agonist (SABA) and an ICS, or 
with a short course of 10 days high dose ICS at the start of exacerbations. In moderate-
severe asthma regularly treated with inhaled ICS/LABA combination, the symptom-driven 
use of the same inhaled ICS/LABA combination as reliever is superior to the symptom-
driven use of SABA or LABA alone. The efficacy of the symptom-driven use of 
ICS/bronchodilator combination on symptoms and exacerbations may be attributed to the 
prompt treatment (bronchodilatation and acute antiinflammatory effects) given at the time 
of worsening symptoms associated with both bronchoconstriction and acute inflammation. 
No study has been performed so far to investigate whether the symptom-driven use of an 
inhaled ICS/LABA combination is equivalent or inferior to the guideline recommended 
regular ICS/LABA combination. This study is needed! First, in Italy more than 50% of 
asthma medication costs is due to fixed ICS/LABA combinations. Also, there is increasing 
concern on the potential adverse events of the regular use both ICS and LABA. Thirdly, 
the compliance with regular treatment is very low, particularly for chronic diseases such 
asthma whose clinical manifestations are quite variable in intensity and frequency. In this 
study we aim to investigate whether a symptom-driven use of formoterol/budesonide is 
non-inferior to the regular use of formoterol/budesonide plus prn use of terbutaline in 
patients with mild-moderate asthma, ie in patients with FEV1>80% predicted that are not 
controlled by regular treatment with low dose inhaled corticosteroids, and thus require a 
step up to regular treatment with ICS/LABA combination. 
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Backround and rationale 
Asthma is a problem worldwide, with an estimated 300 million affected individuals (22). 
There is evidence that asthma prevalence has been increasing in the last decades in some 
countries, including Italy (23, 24). Analyses of the cost of asthma lead to conclude that the 
burden of the disease depend on the extent to which exacerbations are avoided since 
emergency treatment is more expensive than regular treatment (25). In Italy, it has been 
calculated that direct costs represent 47.3% of the total economic burden of the disease, 
medications being the largest component of it(26). In 2001 direct medical costs for asthma 
were above € 800.000.000, i.e. 1% of the entire Italian health care system expenses, asthma 
medications being responsible for € 650.000.000 (27). Asthma is characterized by chronic 
inflammation of the airways with variable airflow limitation resulting in recurrent episodes 
of wheezing, breathlessness, chest tightness and coughing. As inhaled corticosteroids (ICS) 
effectively suppress airway inflammation (28), reduce symptoms and improve lung 
function, they are considered the most effective controller medication currently available 
(25). 
However, recent studies in children negate that regular treatment with ICS affects the 
natural history of asthma (29, 30). Thus, considering the lack of treatments that may 
change the natural history of asthma, the main aim of the treatment is still to reach and 
maintain control of asthma, as defined by the absence of limitations in daily life, of 
troublesome diurnal and nocturnal symptoms, normal or almost normal pulmonary 
function, and prevention of exacerbations (25). Indeed according to the most recent update 
of GINA guidelines, control has become the main determinant of the assessment of 
severity of asthma, as the previously proposed classification based only on symptoms and 
lung function was useful only in untreated patients (25). In this respect, ICS are the best 
mantainance treatment available to achieve and particularly to mantain control (25). 
However, over the past decades maintenance treatment has evolved from ICS alone to 
combination therapy with ICS/long-acting beta2-agonist (LABA) for patients with asthma 
that is not controlled on low doses ICS alone (25), which in addition to improve control is 
associated with reduced need of higher doses of ICS (31, 32). Because of its clinical 
efficacy, the use of ICS/LABA combination therapy is widely diffuse in asthma 
management: in Italy, more than 50% of asthma medication costs iscurrently due to fixed 
ICS/LABA combinations (27). However, such a wide diffusion increases therisks of 
inappropriate (over-) treatment with ICS/LABA combination particularly because the 
efficacy of low doses ICS alone may not be even looked at. Nowadays, there is also 
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increasing concern on the potential adverse events of both ICS and LABA, which 
reinforces the general concept of all asthma guidelines to provide the patients with the 
minimum amount of medication required to achieve and maintain control (25). Indeed, a 
warning has been recently raised on the use of LABA in asthma since they are suspected to 
increase the risk of asthma exacerbations and of asthma deaths even when associated to 
ICS (33). Maintenance treatment generally implies a twice daily regular treatment. 
However, two recent different studies have shown once-daily ICS/LABA dosing to be an 
effective treatment for patients with moderate asthma (34, 35). Short-acting b2 agonists, 
alone, are currently recommended as prn medication for symptom relief at any stage of 
asthma severity, even though symptoms are associated not only with bronchoconstriction 
but also with enhanced airway inflammation (36), and inhaled corticosteroids may rapidly 
exert their anti-inflammatory action (16), enhance the effect of b2 agonists (37), and be as 
effective as systemic corticosteroids in the treatment of mild asthma exacerbations (38). 
While doubling the dose of ICS is ineffective in preventing exacerbations (39), short 
courses of high-dose ICS at the onset of asthmatic exacerbations enhance control (40). 
Also, the control of mild persistent asthma obtained with short courses of high-dose ICS is 
no different from that obtained with regular treatment with low-dose ICS (41). A recent 
study shows that even the simpler symptom-driven rescue use of a ICS/short-acting beta2 
agonist (SABA) combination in a single inhaler in the absence of any regular treatment is 
no different from regular treatment with inhaled corticosteroids in controlling mild 
persistent asthma (42). These findings indicate that persistent suppression of airway 
inflammation, as obtained by regular ICS treatment (28, 43), does not imply a better 
clinical effect as compared to intermittent treatment (41): it may be sufficient to suppress 
the flares of airway inflammation associated with the development of symptoms and 
exacerbations (36, 44). It has also been documented in moderate-severe asthma that a 
symptom-driven rescue use of a ICS/LABA combination in addition to the regular use of 
ICS/LABA combination is superior to the guideline recommended regular use of inhaled 
ICS/LABA combination plus prn use of either a short- or a long- acting beta2-agonist (18). 
Finally, one study has shown that symptom-drived treatment of a formoterol/budesonide 
combination in mild intermittent asthma is more effective both clinically and as 
antiinflammatory than symptom drived use of formoterol alone (45). The effect of the 
symptom-driven rescue use of inhaled corticosteroids plus bronchodilator combination on 
symptoms and exacerbations can be attributed to the prompt treatment (bronchidilatation 
and acute antiinflammatory effects) given at the time of worsening symptoms associated 
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with both bronchoconstriction and acute inflammation. Considering this background, it is 
surprising that the requirement of the regular (i.e. daily assumption) vs intermittent 
treatment with inhaled ICS/LABA combination has never been challenged in moderate 
asthmatics. We speculated that a symptomdriven rescue use of a ICS/LABA combination, 
such as budesonide/formoterol, in the absence of maintenance therapy, would be as 
effective as regular use of budesonide/formoterol combination plus prn use of a SABA in 
patients that are not controlled by regular treatment with low dose inhaled corticosteroids. 
 
Study objectives 
Primary objective 
The aim of the study is to verify whether asthma not controlled by low doses inhaled 
corticosteroids, thus in need for step up therapy, can be equally controlled by guidelines 
recommended regular bid treatment with ICS/LABA combination or the symptom driven 
use of an ICS/LABA combination in the absence of maintenance therapy. The study is 
designed to be able to evaluate the non inferiority of regular placebo plus prn inhaled 
budesonide/formoterol (experimental treatment) versus regular, twice daily 160/4.5 mcg 
inhaled budesonide/formoterol combination plus prn inhaled terbutaline (guidelines 
recommended treatment). 
The primary outcome for comparison between groups will be the time to treatment failure 
defined as the occurrence of any one of the following events: hospitalisations, unscheduled 
medical visit for asthma initiated by the patients or physician, use of systemic CS for 
asthma or open label use of ICS for asthma as determined by physician, nocturnal 
awakenings (2 or more on 2 consecutive days), rescue medication use (4 times or more 
additional puffs per day as compared with baseline last 2 weeks of run-in- on 2 consecutive 
days), refusal of the patient to continue because of lack of satisfaction with treatment, or 
judgement by a physician should stop treatment for reasons of safety (32, 43, 46). Follow-
up will be continued according to protocol after the treatment failures will be noted. 
 
Secondary objectives 
Secondary outcomes will be: 
1. number of treatment failures and of drop-outs, time to first treatment failure and to 
drop-out; 
2. differences between groups of: 
a) morning and evening PEF during the study treatment – 2-wk mean values 
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b) morning and evening PEF measured during the period of intense therapy– 2-wk 
mean values, 
c) lung function parameters measured at study visits and at the end of the period of 
intense therapy 
d) asthma QoL scores, asthma control scores (ACQ), 
e) percent and mean days without rescue medication during the treatment period 
f) percent and mean days without asthma symptoms during the treatment period 
g) percent and mean days of asthma control, i.e. without asthma symptoms and 
without rescue medication, throughout the study 
h) asthma symptom score – 2-wk mean values, and medication use throughout the 
treatment; and also end study changes from baseline of secondary outcomes a to h. 
i) differences between treatment groups of changes (1 to 2h) from the last 2 
weeks/visit of the period of intense therapy and the last 2 weeks/visit of study 
treatment, 
j) cumulative dose of Budesonide and of Formoterol during 1 yr study treatment and 
k) adverse events. 
 
Study design 
This study is a 52 weeks, multicenter, national, double-blind, double-dummy, randomized, 
active drug-controlled, 2-arm parallel group trial in patients with asthma not controlled by 
low doses inhaled corticosteroids comparing, regular placebo plus prn ICS/LABA 
combination (experimental treatment) with the guideline recommended regular bid 
ICS/LABA combination plus prn terbutaline. 
The study will be divided in: 
a) Run-in Period (week –6 to 0) of 6 weeks duration 
b) Treatment period (week 0 to 52) of 52 weeks duration 
c) Follow-up period/Intense Treatment (week 52 to 58) of 6 weeks duration 
 
a. Run-in period (week –6 to week 0) Visit 1 to 2 
Patients meeting the inclusion criteria will enter a 6-weeks run-in period receiving open 
label bid inhaled 160/4.5 mcg budesonide/formoterol combination (Symbicort 
Turbuhaler®) plus prn Terbutaline. At the end of run-in, patients will be elegible for 
recruitement providing they have stable asthma (1), i.e. post-BD FEV1 > 80% and diurnal 
variation < than 20% in PEF, ≤ 2/week daytime symptoms, ≤ 2/week need for rescue 
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treatment, no nocturnal symptom/awakening, no limitation of activities and no use of oral 
corticosteroids during the last 14 days of the run-in. 
Patients meeting the inclusion criteria will be instructed to use: 
1) a peak flow meter (MiniWright®), 
2) a diary to record morning and evening PEF, asthma symptoms, nocturnal awakenings, 
and as needed medication use. 
 
b. Treatment period (week 0 to week 52) Visit 2 to 9 
At the end of the run-in period, elegible patients will be randomized into one of the two 
treatment groups: (i) bid inhaled placebo plus prn inhaled 160/4.5mcg 
budesonide/formoterol combination (experimental treatment); or (ii) bid inhaled 160/4.5 
mcg budesonide/formoterol combination plus prn 500 mcg terbutaline (guidelines 
treatment). 
From run-in onwards, patients will be asked to withdraw any other anti-asthma 
medications, and to use only the study drugs. Up to 8 rescue inhalations/day will be 
allowed. This means a maximum of 10 puffs per day (in total) in the arm blindly treated 
with bid inhaled 160/4.5 mcg budesonide/formoterol combination. Up to 12 puffs a day are 
currently approved for this combination. 
Throughout the study, patients requiring more than 8 rescue inhalations on a single day 
will be asked to refer to a study physician. 
 
c. Follow-up period/Intense Treatment (week 52 to 58) Visit 9 to 10 
The follow-up phase will consist of a 6-weeks period of optimal therapy (SMART 
Symbicort Maintenance and Reliever Therapy) (18), in this period the patients will receive 
the open label medication consisting of intense treatment with 160/4.5 mcg 
budesonide/formoterol combination 1 inalation bid plus prn 160/4.5 mcg 
budesonide/formoterol combination (maximum 8) (Figure 1). 
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METHODS 
 
Clinic visits will take place at the beginning (visit 1) and end (visit 2) of the run-in period, 
and then after 4, 12, 20, 28, 36, 44, 52 (visit 9) weeks of treatment. Visit 10 will take place 
at the end of the 6 week treatment phase at week 58. At study visits, the investigator will 
review the diary cards and verify treatment compliance; physical examination will be 
performed, blood pressure, heart rate, and lung function measured, and asthma symptoms, 
asthma exacerbations, and adverse events will be reported and asthma control 
questionnaire (ACQ) (47) will be administered. 
On clinic visits’ days, patient will be asked to abstain from the morning inhalation of the 
study drug. At each study visit, post-bronchodilator lung function will be measured 30 
mins after inhalation of open labelled 160/4.5mcg budesonide/formoterol combination (1 
inhalation). 
The asthma related quality of life will be assessed by means of a questionnaire at 
enrolment and at the end of treatment, and end of the intense treatment period (48). 
Episodes of decreased morning PEF of more than 20% below the baseline value for 2 or 
more consecutive days (with or without the clinical conditions of a treatment failure), will 
be counted separately. Also, episodes of decreased morning PEF of more than 30% below 
the baseline value on 2 consecutive days (with or without the clinical conditions of a 
treatment failure), will be counted separately (43). 
Each subject will be involved in the study for 64 weeks. This period will be divided into 
three phases: a 6-week run-in period, a 52 week treatment period, a 6-week follow-up 
period. 
Recruitment starting from April 2009 and continuing until May 31, 2012. At study 
completion, final study report will be available after full data analysis. 
Organization of the study will start as soon as approval is received. 
According to data from previous trials, the percentage of patients with treatment failure at 
1 year in the regular use of Budesonide/Formoterol combination bid group is expected to 
be approximately 35%. A non-inferiority margin of 9% at 1 year, i.e., a percentage of 
patients with treatment failure at 1 year in the prn Budesonide/Formoterol combination 
group of approximately 43%, is considered to be clinically acceptable. 
Under the assumptions stated above, a total number of 355 events (ie patients with at least 
one event) are required to test the non-inferiority (one-sided test at 0.025 significance 
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level) of the time to treatment failure of the prn Budesonide/Formoterol combination group 
vs regular use of Budesonide/Formoterol combination bid with a power of at least 80%. 
Planning that patients will be enrolled roughly uniformly over a period of 1 year and that 
the primary analysis of time to treatment failure will be performed 1 year after the last 
patient is accrued, there will be 860 evaluable subjects, 430 in each of the two treatment 
group. 
Given an estimated dropout rate of 10%, approximately 960 subjects will be enrolled in the 
study in about 33 Italian centres. 
The 33 Clinical units participating the study are expected to recruit about 32 
patients/center. 
Randomization procedure will be centralized in the Clinical Research Office of the 
University of Modena (R. D'Amico). Patients will be randomized according to a list 
prepared using a SAS random number generator procedure. Each investigator will be 
assigned the lowest available number at his site according to chronological order of entry 
at recruitment. The same DPI device (Turbuhaler®) will be used in all groups and 
treatments to ensure a double-blind design. The devices containing regular treatments will 
be labelled “Trattamento Regolare, 1 inalazione al mattino e 1 inalazione alla sera”, while 
those for prn treatment will be labelled “Da usare al bisogno”. Patients will be instructed to 
take 1 inhalation in the morning and 1 in the evening from the device labelled 
“Trattamento Regolare, 1 inalazione al mattino e 1 inalazione alla sera” and one or more 
inhalations when needed for symptoms relief from the labelled “Da usare al bisogno”. 
Patients will be instructed to measure morning and evening PEF before taking the study 
medication and to record daily asthma symptoms, number of nocturnal awakenings, study 
drug intake and number of rescue inhalations. Daytime symptoms will be evaluated in the 
evening on a 4-point scale ranging from 0 (no symptoms) to 4 (symptoms for most of the 
day which affected normal daily activities), whereas nighttime symptoms will be evaluated 
in the morning on a 4-point scale ranging from 0 (no symptoms during the night) to 4 
(symptoms so severe that they not allow the patient to sleep at all). 
 
Study Population 
The subjects to recruit in this study protocol are asthmatic patients either not controlled by 
ICS (≤500 mcg BDP/d or equivalent) or controlled with the fixed combination of low 
doses ICS+LABA bid (step 3 GINA 2006), i.e. patients that have initiated this treatment 
with combination therapy in the last year because not controlled by low doses ICS. 
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Inclusion criteria 
 Male or female out-patient aged ³ 18 years and £ 65 years 
 Clinical diagnosis of moderate persistent asthma for at least 6 months, according to 
GINA revised version 2006 guidelines 
 Post-bronchodilator forced expiratory volume (FEV1)³ 80% of the predicted. 
 Either positive methacholine challenge test (PC20 FEV1< 4mg/ml or PD20 FEV1<0.8 
mg) or positive response to the reversibility test in the last year 
 Asthma either not adequately controlled with low-dose (≤500 mcg bechlomethasone 
or equivalent) inhaled corticosteroids (ICS) or controlled (as defined below*) by bid 
inhaled combination of lowdose ICS/long acting beta-2 agonists (LABA) i.e. patients 
that have initiated this treatment with combination therapy in the last year because not 
controlled (as defined below*) by low doses ICS 
 A co-operative attitude and ability to be trained to correctly use the dry powder 
inhalator and to complete the diary cards 
 Written informed consent obtained in the last month ≤2 week daytime symptoms; 
≤2/week need for rescue treatment, no nocturnal symptom, awakening, no limitation 
of activities, and no use of oral corticosteroids 
 
Exclusion criteria 
 Inability to carry out pulmonary function testing 
 moderate severe asthma associated with reduced lung function 
 history of near-fatal asthma and/or admission intensive care unit because of asthma, 
 3 or more courses of oral corticosteroids or hospitalization for asthma during the 
previous year. 
 Diagnosis of COPD as defined by the GOLD guidelines 
 Evidence of severe asthma exacerbation or symptomatic infection of the airways in the 
previous 8 weeks 
 Current smokers or recent (less than one year) ex-smokers, defined as smoking at least 
10 pack/years; 
 History or current evidence of heart failure, coronary artery disease, myocardial 
infarction, severe hypertension, or cardiac arrhythmias 
 Diabetes mellitus 
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 Percutaneous transluminal coronary angioplasty (PTCA) or coronary artery by-pass 
graft (CABG) during the previous six months 
 Abnormal ECG 
 Clinically significant or unstable concurrent diseases: uncontrolled hyperthyroidism, 
significant hepatic impairment, poorly controlled pulmonary disease (tuberculosis, 
active mycotic infection of the lung), gastrointestinal (e.g. active peptic ulcer), 
neurological or haematological autoimmune diseases 
 Malignancy 
 Any chronic diseases with prognosis < 2 years 
 Pregnant or lactating females or not able to esclude pregnancy during the study period 
 History of alcohol or drug abuse 
 Patients treated with monoamine oxidase inhibitors, tricyclic antidepressants or beta-
blockers as regular use 
 Allergy, sensitivity or intolerance to study drugs and/or study drug formulation 
ingredients 
 Patients unlikely to comply with the protocol or unable to understand the nature, scope 
and possible consequences of the study 
 Patients who received any investigational new drug within the last 12 weeks 
 Patients who have been previously enrolled in this study  
 
Withdrawal criteria 
Patients have the right to withdraw from the study at any time for any reason, including 
personal reasons. The Investigators have also the right to withdraw patients from the study 
in the event of intercurrent illness that necessitates pharmacological treatment with a 
disallowed drug, in case of an adverse event, treatment failure, protocol violations, poor 
compliance, pregnancy or any other reason. 
 
Treatment failure 
Treatment failure is defined as the occurrence of any one of the following events: 
 hospitalisations, 
 unscheduled medical visits for asthma initiated by the patients or physician, 
 use of systemic CS for asthma or 
 open label use of ICS for asthma as determined by physician 
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 nocturnal awakenings (2 or more on 2 consecutive days), 
 rescue medication use (4 times or more additional puffs per day as compared with 
baselinelast 2 weeks of run-in- on 2 consecutive days), 
 refusal of the patient to continue because of lack of satisfaction with treatment, or  
 judgement by a physician should stop treatment for reasons of safety. 
According to data from previous trials, the percentage of patients with treatment failure at 
1 year in the regular use of Budesonide/Formoterol combination bid group is expected to 
be approximately 35%. A non-inferiority margin of 9% at 1 year, i.e., a percentage of 
patients with treatment failure at 1 year in the prn Budesonide/Formoterol combination 
group of approximately 43%, is considered to be clinically acceptable. 
 
Statistics 
All statistical analyses and data processing were performed using Statistical Analysis 
Systems (SAS®) Software (release 9.2) on a Windows 7 operating system. 
The rate of patients in the regular budesonide/formoterol group with treatment failure at 
one year was estimated at 35%, and a non-inferiority margin of 9% at one year was 
considered clinically acceptable, based on an estimated effect size of 17%.
7,26
 A total of 
355 treatment failures (in patients with at least one) were required to test the non-
inferiority (one-sided test at 0·025 significance level) of the time to treatment failure of the 
PRN budesonide/formoterol group versus the regular combination group, with a power of 
at least 80%. A total of 860 evaluable patients, 430 in each group, were required to satisfy 
the above hypothesis.  
Kaplan-Meier estimates were used to evaluate the time to treatment failure and the 
probability of patients with no treatment failure at 1 year. Time to treatment failure was 
also analysed by using a Cox proportional hazards regression model, including only 
treatment in the model. 
Methods for the sensitivity analyses of the primary outcome, and ANCOVA models for 
secondary quantitative endpoints are described in the Appendix. A post-hoc analysis was 
performed to evaluate the effects of baseline risk factors/covariates on the probability of 
treatment failure by means of a logistic analysis. The primary endpoint was assessed both 
in the ITT and PP population, where the ITT analysis included all randomized patients who 
received at least one administration of the study medication and who had at least one 
available post-baseline efficacy evaluation and the PP population excluded from the ITT 
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the efficacy data collected after the start date of the major protocol deviation. All 
secondary endpoint were analysed in the ITT population. 
 
Role of the funding source 
The study was funded by the Italian Medicines Agency (www.agenziafarmaco.gov.it, 
Agenzia Italiana del Farmaco, AIFA, FARM6BWSF9) of the Italian Ministry of Health 
(www.salute.gov.it). All drugs were donated by AstraZeneca (AstraZeneca S.p.a. Basiglio, 
Milano, Italy), which had no role in the study design. 
Data were collected by the clinical investigators, analysed by CROS NT (Verona, Italy), 
and discussed by the clinical investigators. AstraZeneca had no role in data collection and 
analyses, and in drafting the manuscript, nor was informed of the results of the study. The 
corresponding author had full access to all of the data and the final responsibility to submit 
for publication. 
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RESULTS  
 
A total of 1,010 patients were screened, and 866 were randomised (424 in the PRN 
budesonide/formoterol group and 442 in the regular budesonide/formoterol group). Figure 
1 shows the disposition of patients. The number of patients who actually received 
treatment (safety population) was 419 in the PRN budesonide/formoterol group and 437 in 
the regular budesonide/formoterol group. The intention-to-treat (ITT) population included 
394 and 423 patients, respectively, and the protocol (PP) population included 393 and 422 
patients, respectively.  
Treatment groups were well matched in demographic and clinical characteristics at 
baseline (Table 3). Compliance to treatment at the end of the study period (visit 9) was of 
85% (SD: 27%) and of 83% (SD: 26%) in the PRN and regular budesonide/formoterol 
groups, respectively (51). 
 
Primary efficacy outcome 
Compared to regular budesonide/formoterol therapy, patients in the PRN 
budesonide/formoterol group had shorter time to treatment failure (Table 4 and Figure 2) 
and higher probability of treatment failure (Kaplan Meier estimates, 53.6% vs 64.0%; 
difference: 10.3%, 95% CI: 3.2%, 17.4%, pre-defined non-inferiority limit: 9%) at one 
year (Table 4 and Figure 2) in the ITT population analysis. The hazard ratio between the 
two groups was 1.49 (95% CI, 1.19 to 1.87). The two curves for the 2 groups were resulted 
to be parallel and this confirmed the proportional hazards assumption. In addition we tested 
the correlation of the scaled Schoenfeld residuals on functions of time for both the ITT and 
PP population. The Pearson correlation was not statistically significant and for this reason 
there was not a violation of the proportional hazard assumption. 
The cumulative number of patients experiencing treatment failure during the one-year 
study period was 170 (43.1%) in the PRN budesonide/formoterol group and 139 (32.9%) 
in the regular budesonide/formoterol group.  
The results observed in the PP analysis were consistent with those in the ITT population 
(Table 4). The pre-planned sensitivity analyses, which treated drop-outs as treatment 
failures (Figure 2), confirmed the robustness of the results of the primary outcome. The 
most common reason for treatment failure was two nocturnal awakening on two 
consecutive days (82 patients in the PRN budesonide/formoterol group and 44 in the 
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regular budesonide/formoterol group). This was the only component of the composite 
primary outcome that differed significantly between groups (p<0.001) (Table 4a). The 
mean percentage of days with nocturnal awakenings was 16·17 (SD: 23.94) and 7.94 (SD: 
16.07) in the PRN budesonide/formoterol and in the regular budesonide/formoterol group 
respectively. Female sex and smoking habit in the PRN budesonide/formoterol group, and 
baseline Asthma Control Questionnaire score overall and in both groups, were the factors 
significantly associated with higher risk of failure (Figure 3). 
 
Secondary efficacy outcomes 
The time to drop-out was shorter in the PRN budesonide/formoterol group (28 versus 48 
days, representing the time until at least 25% of the patients [first quartile] dropped out of 
the study; p=0.009 between groups in the log-rank test). Figure 3, shows the Kaplan-Meier 
plot for the time to drop-out in the ITT population. The cumulative number of patients who 
dropped out at the end of the randomised treatment phase was 133 (31.4%) in the PRN 
budesonide/formoterol group and 108 (24.4%) in the regular budesonide/formoterol group; 
Kaplan Meier estimates, 34.0% vs 25.9%, p=0.009). 
Table 2b shows the results of the other secondary outcomes. From baseline to the end of 
treatment in the randomised phase of the study, there were significant differences between 
the two groups, in favour of regular budesonide/formoterol therapy.  
After the follow-up period with open-label SMART budesonide/formoterol therapy only 
morning PEF (p=0.02), number of puffs of rescue medication (p=0.01), and percentage of 
days without use of rescue medication (p=0.004) were still significantly different in favour 
of regular budesonide/formoterol therapy. 
 
Safety 
Patients on PRN budesonide/formoterol combination used significantly more rescue 
medications, and the difference, albeit small, remained significant even at the end of the 
follow-up. The estimated cumulative dose of budesonide (116.8 vs 24.5 mg/year) and 
formoterol (3.2 mg vs 0.69 mg/year) was obviously larger in patients treated with regular 
budesonide/formoterol combination.  
A part from the number of patients with oropharyngeal pain, the number of patients with 
treatment-emergent adverse events (TEAEs) was no different between the two groups 
(Table 4). Similarly, there were no differences in the number of patients with adverse 
reactions. Worsening of asthma was the most common TEAE: 48 patients (11.5%) in the 
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PRN budesonide/formoterol group and 40 (9.2%) in the regular budesonide/formoterol 
group (Table 4). From baseline to the end of the treatment period, morning serum cortisol 
showed no evidence of adrenal suppression in either group (data not shown). 
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DISCUSSION  
 
In this one-year, randomised, double-blind, clinical trial conducted in moderate asthmatics, 
PRN budesonide/formoterol was inferior to regular budesonide/formoterol combination 
plus PRN terbutaline in preventing treatment failure. These results confirm the guideline 
recommended regular LABA/ICS combination treatment for patients not adequately 
controlled by regular ICS (1). 
Nocturnal awakenings were the only component of treatment failure that was not protected 
by the PRN budesonide/formoterol therapy, most likely either because of lack of protection 
offered by the regular treatment or lack of prompt reversal of nocturnal symptoms by the 
PRN budesonide/formoterol combination treatment. The overall increased number of 
nocturnal awakening in the PRN budesonide/formoterol group was 38 episodes of 
nocturnal awakening in two consecutive nights in one year for the 394 patients in the ITT 
population, i.e. an average risk of one episode of nocturnal awakening in two consecutive 
night per patient in ten years, which may be considered of limited clinical relevance. The 
other difference between the two treatments was the higher drop-out from the study in 
patients on PRN budesonide/formoterol treatment (41.3% in the PRN 
budesonide/formoterol group and 31·2% in the regular budesonide/formoterol group). The 
drop-out was reported to be not related to efficacy or safety reasons, but mainly to consent 
withdrawn (11.5% vs 14.6%) and other logistic reasons. In a relatively young and actively 
working population, it is not totally surprising that the willingness (and possibility) to 
follow the strict rules-visit intervals- of a RCT for one entire year may be too demanding, 
and thus patients withdrew their consent (the main dropout reason; the same for logistic 
reasons), especially in a non-sponsored study, like the present one, where patients received 
no payment nor expense reimbursement for the participation to the study. However, the 
difference between the two groups (5.4% vs 8.0%) further suggest inferiority of the PRN 
budesonide/formoterol treatment. The results of the sensitivity analyses that took into 
account the study drop-outs confirmed the results of the primary analysis, excluding that 
they might have been affected by the different drop out. 
Because of the characteristics of the population examined, i.e., patients with moderate 
asthma well controlled by the regular ICS/LABA combination—hence, not at high risk of 
exacerbations—the primary outcome of our study was rate to treatment failure. Indeed 
there were only 117 severe exacerbations (defined as treatment with steroids and/or 
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admission to the emergency room/hospital) in 817 patients during the one-year study 
(0.143 per patient per year): 53 (none hospitalized) in the PRN budesonide/formoterol 
group (0.135 per patient per year) and 64 (4 hospitalized) in the regular 
budesonide/formoterol group (0.151 per patient per year). Thus, both therapies were 
associated with a very low incidence of severe exacerbations, possibly because they were 
both effective in controlling exacerbations.  
Poor adherence in the regular treatment might have reduced the difference in medication 
use between the two groups, thereby contributing the small differences in outcomes at the 
end of the study. In fact, Patel et al
8
 recently reported that adherence is lower in regular 
compared to SMART treatment and falls progressively over six and 12 months, suggesting 
that poor adherence to regular maintenance treatment might have influenced the small 
differences in outcomes that we observed in our study. However, the differences observed 
in our study likely reflect what would happen in real life by adopting the two different 
strategies compared in this study. 
After the one-year randomised treatment, both groups of patients received a six-week 
SMART treatment with both maintenance and reliever budesonide/formoterol therapy to 
reverse uncontrolled components of asthma, if any. Both groups improved clinically and in 
most measurements of lung function made in the clinic (FVC, FEV1, and PEF). These 
values returned to baseline, suggesting there had been no irreversible decline in lung 
function. However, morning PEF measured by the patient at home decreased significantly 
in the PRN budesonide/formoterol group and did not return to baseline after six weeks of 
SMART treatment. The reasons for the discrepancy between measurements of lung 
function made by the patient and in the clinic remain unclear (49). Although the decrease 
in morning PEF may suggest that the PRN budesonide/formoterol therapy may be 
associated with a decline in pulmonary function that was not reversible even after six 
weeks of SMART treatment with budesonide/formoterol, the fact that such a decline was 
not observed in clinically assessed PEF, FVC and FEV1 is reassuring. 
The use of rescue medication and the percentage of days without the use of rescue 
medication remained significantly different between groups at the end of the six-week 
SMART follow-up therapy, suggesting that long-term PRN therapy may be associated with 
some persistent small reduction of control. 
As expected, the number of patients with adverse reactions was low in both groups and, 
apart from the predictable oropharyngeal pain possibly related to the regular use of inhaled 
steroids, there were no other difference between groups, suggesting that safety is not an 
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issue in considering the two alternative therapies, at least from a one-year perspective. In 
particular, the use of a less intensive regimen in the PRN budesonide/formoterol group did 
not result in a lower risk of adverse events compared to the regular budesonide/formoterol 
group.  
The study had some weaknesses. Two centers that initially agreed to participate in the 
study withdrew afterwards their willingness to participate/participation for logistic at local 
reasons. No patients were randomized in these centers and entered in the analysis. Also, 
due to the limited budget, monitoring of the centers was mainly made via 
teleconferences/internet and not with direct site-visits as usually performed in 
pharmaceutically sponsored randomized clinical trials. Moreover, paper diary card 
consisted a limitation for the completeness of the data related to PEF/symptoms data. This 
problem is well known in clinical research and the use of ePRO is more frequent to limit 
this aspect. The limitation of the budget was not allowing though the use of these tools. 
In conclusion, the results of this study show that PRN budesonide/formoterol is inferior to 
regular budesonide/formoterol plus PRN terbutaline in preventing treatment failure and in 
maintaining control. However, because the differences were small and the level of control 
remained above partially controlled asthma,
 
we speculate that in recommending the regular 
combination treatment according to guidelines, the results of this study could be discussed 
with the patient, particularly reinforcing the recommendation of regular treatment with 
LABA/ICS combination to female patients and to patients with a significant smoking 
history who have a higher risk of loss of asthma control with PRN combination treatment 
(50),(Figure 3). Other patients could be presented with the advantages of a PRN treatment 
(convenience, lower cumulative dose of medications, potential long-term safety) to balance 
the disadvantages (lower level of control of asthma with occasional nocturnal awakening, 
increased use of rescue medication) (51). 
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TABLES AND FIGURES 
 
Table 1: Differential diagnosis of asthma  
Localized pathology Inhaled foreign body 
Endobronchial tumour 
Vocal cord dysfunction 
Diffuse airway pathology COPD 
Eosinophilic bronchitis 
Bronchiectasis 
Other pathologies Gastroesophageal reflux  
Left ventricular failure 
Pulmonary embolism 
Pulmonary eosinophilia 
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Table 2. Inclusion and exclusion criteria. 
Inclusion criteria Exclusion criteria 
1. Male or female out-patient aged 18 years and 
65 years;  
2. Clinical diagnosis of moderate persistent asthma 
for at least 6 months, according to GINA revised 
version 2006 guidelines;  
3. Post-bronchodilator forced expiratory volume in 
1 s (FEV1) 80% of the predicted;  
4. Either positive methacholine challenge test (PC20 
FEV1 <4 mg/ml or PD20 FEV1 <0·8 mg) or 
positive response to the reversibility* test in the 
last year;  
5. Asthma either not adequately controlled with 
low-dose (≤500 µg beclomethasone or 
equivalent) ICS or controlled (as defined below^) 
by b.i.d. inhaled combination of low-dose 
ICS/LABA, i.e., patients who had initiated this 
treatment with combination therapy in the last 
year because asthma not controlled (as defined 
below*) by low-dose ICS; 
6. A cooperative attitude and ability to be trained to 
correctly use the Turbuhaler
® 
DPI and to 
complete the diary cards;  
7. Written informed consent obtained. 
* In the last month, ≤2 week daytime symptoms, 
≤2/week need for rescue treatment, no nocturnal 
symptoms or awakening, no limitation of 
activities, and no use of oral corticosteroids. 
1. Inability to carry out pulmonary function testing;  
2. Moderate severe asthma associated with reduced 
lung function; 
3. History of near-fatal asthma and/or admission to 
intensive care unit because of asthma; 
4. Three or more courses of oral corticosteroids or 
hospitalisation for asthma during the previous 
year; 
5. Diagnosis of COPD as defined by the GOLD 
guidelines;  
6. Evidence of severe asthma exacerbation or 
symptomatic infection of the airways in the 
previous 8 weeks;  
7. Current smokers or recent (<1 year) ex-smokers, 
defined as smoking at least 10 pack/years; 
8. History or current evidence of heart failure, 
coronary artery disease, myocardial infarction, 
severe hypertension, or cardiac arrhythmias;  
9. Diabetes mellitus; 
10. Percutaneous transluminal coronary angioplasty 
(PTCA) or coronary artery by-pass graft (CABG) 
during the previous 6 months; 
11. Abnormal ECG; 
12. Clinically significant or unstable concurrent 
diseases: uncontrolled hyperthyroidism, 
significant hepatic impairment, poorly controlled 
pulmonary disease (tuberculosis, active mycotic 
infection of the lung), gastrointestinal (e.g., 
active peptic ulcer), neurological or 
haematological autoimmune diseases; 
13. Malignancy; 
14. Any chronic diseases with prognosis <2 years;  
15. Pregnant or lactating females or not able to 
exclude pregnancy during the study period;  
16. History of alcohol or drug abuse;  
17. Patients treated with monoamine oxidase 
inhibitors (MAOIs), tricyclic antidepressants or 
beta-blockers as regular use;  
18. Allergy, sensitivity or intolerance to study drugs 
and/or study drug formulation ingredients;  
19. Patients unlikely to comply with the protocol or 
unable to understand the nature, scope and 
possible consequences of the study;  
20. Patients who received any investigational new 
drug within the last 12 weeks;  
21. Patients who had been previously enrolled in this 
study. 
^positive response to reversibility was considered a post-bronchodilator  (400 ug 
salbutamol) FEV1 increase of at least 200 mL and 12% from the pre-bronchodilator values, 
according to GINA 2006 recommendations (www-ginasthma.org). 
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Table 3. Demographic and clinical characteristics of patients at baseline (ITT population) 
  PRN 
budesonide/formoterol 
(N=394) 
Regular 
budesonide/formoterol 
(N=423) 
Sex, N (%) 
   Males 
   Females 
  
153 (38.8%) 
241 (61.2%) 
  
185 (43.7%) 
238 (56.3%) 
Age, years (mean  SD) 42·1  12·8 (N=392)  43·2  12·6 (N=423)  
Ethnic origin, N (%) 
  White 
  Asian 
  Black 
  Other 
  Missing 
  
382 (97.0%) 
5 (1.3%) 
4 (1.0%) 
3 (0.8%) 
0 (0.0%) 
  
415 (98.1%) 
3 (0.7%) 
1 (0.2%) 
3 (0.7%) 
1 (0.2%) 
Weight, kg (mean  SD) 71.93  16.33 (N=393) 73.10  16.01 (N=422) 
Height, cm (mean  SD) 166.6  9.60 (N=393) 166.5  9.80 (N=422) 
BMI, kg/m2 (mean  SD) 25.87  5.35 (N=393) 26.31  5.09 (N=422) 
Asthma duration, years (mean  SD) 10.95  10.27 (N=393)   10.99  10.68 (N=419)   
Morning PEF, L/min (mean  SD) 402.02  121.50 
(N=363) 
414.11  120.08 
(N=395) 
Evening PEF, L/min (mean  SD) 406.51  121.66 
(N=362) 
419.99  121.03 
(N=393) 
Pre-bronchodilator FEV1, L (mean  SD) 2.91  0.84 (N=393)  2.95  0.81 (N=419) 
Pre-bronchodilator FEV1 Pred, % (mean  SD) 93.59  21.54 (N=393) 94.58  14.33 (N=418) 
Post-bronchodilator FEV1, L (mean  SD) 3.01  0.85 (N=379) 3.06  0.83 (N=406) 
Post-bronchodilator FEV1 Pred, % (mean  SD) 96.70  22.00 (N=379)  97.73  14.76 (N=405) 
Pre-bronchodilator FVC, L (mean  SD) 3.86  1.03 (N=393) 3.92  1.02 (N=419) 
Asthma symptoms, score (mean  SD) 0.11  0.30 (N=364) 0.06  0.18 (N=388) 
Rescue medication, puffs/day (mean  SD) 0.13  0.52 (N=352) 0.06  0.21 (N=377) 
ACQ, score (mean  SD) 0.57  0.68 (N=375) 0.52  0.64 (N=401) 
AQLQ, score (mean  SD) 6.03  0.94 (N=363) 6.00  0.81 (N=401) 
Use of regular LABA/ICS combination therapy 
in the last year, N (%) 
104 (26.4%) 119 (28.1%) 
 
N = number of patients; ACQ = Asthma Control Questionnaire; AQLQ = Asthma-Related Quality of Life 
Questionnaire. 
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Table 4. Primary and secondary outcomes 
Table 4a. Primary outcome: time to treatment failure in the ITT population 
  PRN 
budesonide/ 
formoterol 
(N=394) 
Regular  
budesonide/ 
formoterol  
(N=423) 
 
Probability of no treatment failure   at 1 year,  
Kaplan Meier estimate (SE) 
 
0.536 (0.026) 
 
0.640 (0.025) 
Difference between the PRN budesonide/formoterol 
therapy and the regular budesonide/formoterol 
therapy Two-sided 95% CI 
 
Time to treatment failure during treatment period 
Hazard ratio Two-sided 95% CI 
 
0.103 
0.032, 0.174 
 
1.491 
1.192, 1.866 
  
 
Patients who experienced at least one treatment 
failure  
 
170 (43.1%) 
 
139 (32.9%) 
Reasons for first treatment failure (N)   
     Hospitalisation 0 3 
     Treatment stopped for safety reasons 
(physician’s judgment) 
24 23 
     Refusal to continue because of patient 
dissatisfaction with treatment 
6 4 
     Episodes of wo nocturnal awakenings on two  
consecutive days 
82 44 
     Unscheduled medical visit for asthma worsening 6 8 
     Use of rescue medication 17 18 
     Use of systemic CS or ICS for asthma worsening 51 59 
     Use of systemic CS for asthma worsening                  31 31 
     Use of ICS for asthma worsening                                 20 28 
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Table 4b. Secondary outcomes (ITT population)  
  PRN 
budesonide/formoterol 
(N=394) 
Regular 
budesonide/formoterol 
(N=423) 
Difference between 
adjusted means 
(Regular vs PRN) 
Pulmonary function    
Morning PEF, L/min(N)* 
    Mean change  SD  
    95% CI 
    P-value 
191 
–22.73  55.26 
–31.18 to –14.29 
 
234 
–2.61  41.89 
–8.25 to 3.04 
 
 
23.127 
13.406, 32.847   
p<0.001 
Evening PEF, L/min (N)* 
    Mean change  SD  
    95% CI 
    P-value 
190 
–21.39  56.27 
–30.01 to –12.76 
 
230 
–4.21  43.62 
–10.15 to 1.74 
 
 
19.882 
9.766, 29.998 
p<0.001 
FEV1, L (N) 
    Mean change  SD  
    95% CI 
    P-value 
244 
–0.16  0.37 
–0.20 to –0.11 
 
305 
–0.01  0.34 
–0.05 to 0.03 
 
 
0·146  
0.088, 0.204 
p<0.001 
FEV1 pred, % (N) 
    Mean change  SD  
    95% CI 
    P-value 
Post-bd FEV1, L (N) 
    Mean change  SD  
    95% CI 
    P-value 
244 
–3.47  12.40 
–5.03 to –1.91 
 
232 
–0.08 0.31 
–0.12 to –0.04 
 
305 
–0.02  11.95 
–1.38 to 1.33 
 
294 
0.06  0.34 
0.02 to 0.10 
 
 
3.605  
1.715, 5.494 
p<0.001 
 
0.137 
0.080, 0.194 
p<0.001 
Post-bd FEV1 pred, % (N) 
    Mean change  SD  
    95% CI 
    P-value 
FVC, L (N) 
    Mean change  SD  
    95% CI 
    P-value 
232 
–0.81  12.76 
–2.48 to 0.86 
 
244 
–0.10  0.39 
–0.15 to –0.05 
 
293 
2.33  12.65 
0.85 to 3.81 
 
305 
–0.02  0.38 
–0.06 to 0.03 
 
 
3.082  
0.998, 5.166 
p=0.004 
 
0.079 
0.015, 0.142 
p=0.015 
PEF, L/min (N)** 
    Mean change  SD  
    95% CI 
    P-value 
244 
–33.96  97.22  
–46.22 to –21.70 
 
305 
–13.64  99.40 
–24.91 to –2.36 
 
 
20.863  
6.921, 34.804 
p=0.003 
Asthma symptoms    
Symptoms score (N)* 
    Mean change  SD  
    95% CI 
    P-value 
194 
0.14  0.43 
0.07 to 0.20 
 
225 
0.05  0.29 
0.01 to 0.10 
 
 
–0.103 
–0.177, –0.029  
p=0.006 
% of days without symptoms 
(N)* 
    Mean change  SD  
    95% CI 
    P-value 
194 
–15.46  37.29 
–21.14 to –9.78 
 
225 
–4.95  27.75 
–8.81 to –1.09 
 
 
11.886 
5.409, 18.363 
p<0.001 
Use of rescue medication    
Rescue medication, puffs/day 
(N)* 
    Mean change  SD  
    95% CI 
    P-value 
187 
0.42  0.82 
0.29 to 0.55 
 
219 
0.12  0.52 
0.05 to 0.19 
 
 
–0.304 
–0.499, –0.159 
p<0.001 
% of days without rescue (N)* 
    Mean change  SD  
    95% CI 
    P-value 
 
187 
–23.80  38.51 
–29.83 to –17.77 
 
219 
–6.38  25.33 
–9.95 to –2.82 
 
 
18.036 
11.292, 24.779 
p<0.001 
Asthma control    
35 
ACQ, score (N) 
    Mean change  SD  
    95% CI 
    P-value 
231 
0.25  0.92 
0·12 to 0.37 
 
293 
0.06  0.74 
–0.03 to 0.15 
 
 
–0.207 
–0.337, –0.077 
p=0.002 
% of days of asthma control 
(N)* 
    Mean change  SD  
    95% CI 
    P-value 
185 
–21.65  40.85 
–28.07 to –15.23 
 
217 
–6.53  29.67 
–10.74 to –2.32 
 
 
16·859 
9.646, 24.072  
p<0.001 
Quality of life    
AQLQ, score (N) 
    Mean change  SD  
    95% CI 
    P-value 
236 
–0.11  1.01 
–0.25 to 0.02 
 
292 
0.07  0.75 
–0.02 to 0.16 
 
 
0.220 
0.086, 0.354   
p=0.001 
 
*in the 2 weeks preceding the medical visit. 
**measured at sites. 
 
Data are expressed as changes from baseline to the end of randomised treatment (week 52). All 
measurements were performed pre-bronchodilator unless otherwise indicated. 
 
N = number of patients; ACQ = Asthma Control Questionnaire; AQLQ = Asthma-Related Quality of Life 
Questionnaire. 
 
Morning PEF, Evening PEF, Asthma Symptoms Score, % days without symptoms, rescue Medication and % 
of Day without Rescue Medication are analysed excluding from the analysis the diary card measurements 
where the patients entered less than 75% data in the last 2 weeks before the visit (i.e. < 10 days over the 2 
weeks preceding a study visit). 
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Table 5. Treatment failure  in the PP population 
  PRN 
budesonide/ 
formoterol 
(N=393) 
Regularbudesonide 
/formoterol (N=422) 
Probability of no treatment failure at 1 year, 
Kaplan Meier estimate mean (SE) 
0.536 (0.027) 0.644 (0.025) 
Difference between the PRN 
budesonide/formoterol group and the regular 
budesonide/formoterol group 
     Two-sided 95% CI 
Hazard ratio 
     Two-sided 95% CI 
 
0.109 
0.037, 0.180 
1.518 
1.211, 1.903 
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Results of the efficacy and safety outcomes (ITT population) at the end of the 6-week 
follow-up SMART therapy 
 
  
PRN 
budesonide/ 
formoterol 
therapy (N=394) 
Regular 
budesonide/formoterol 
therapy (N=423) 
Difference 
between 
adjusted means 
(Regular vs 
PRN) 
Pulmonary function    
Morning PEF, L/min (N)* 
Mean change  SD  
95% CI 
192 
–14.59  59.58 
–23.72 to –5.46 
221 
–3.92  42.88 
–9.97 to 2.14 
 
 12.688 
 (1.923, 23.453) 
    P-value 
Evening PEF, L/min (N)* 
    Mean change  SD  
    95% CI 
 
194 
–11.31  62.50 
–20.85 to –1.76 
 
219 
–4.89  44.24 
–11.15 to 1.38 
p=0.021 
 
8.188 
(–3.005, 19.381) 
    P-value 
FEV1, L (N) 
    Mean change  SD 
    95% CI 
    P-value 
FEV1 pred, % (N) 
    Mean change  SD 
    95% CI 
    P-value 
 
245 
–0.01  0.45  
–0.07 to 0.04 
 
245 
0.05  11.24  
–1.36 to 1.46 
 
 
298 
–0.02  0.33 
–0.06 to 0.02 
 
298 
0.09  10.28  
–1.10 to 1.27 
 
p=0.151  
 
–0.004 
(–0.070, 0.063) 
p=0.910 
 
0.360  
(–1.368, 2.088)  
p=0.683 
Post-bd FEV1, L (N) 
    Mean change  SD  
    95% CI 
229 
0.03  0.28 
–0.01 to 0.06 
284 
0.03  0.33 
–0.01 to 0.07 
 
0.009 
 (–0.045, 0.064) 
    P-value 
Post-bd FEV1 pred, % (N) 
    Mean change  SD 
    95% CI 
    P-value 
FVC, L (N) 
    Mean change  SD  
    95% CI 
    P-value 
 
229 
1.70 to 12.35 
0.07 to 3.33 
 
245 
–0.03  0.36 
–0.08 to 0.01 
283 
1.90 to 11.10 
0.59 to 3.21 
 
298 
–0.03  0.37 
–0.07 to 0.02 
p=0.730 
 
0.530 
(–1.394, 2.454) 
p=0.589 
 
0.011 
(–0.051, 0.073) 
p=0.731 
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PEF, L/min (N)** 
    Mean change  SD  
    95% CI 
    P-value 
245 
–17.97  84.80 
–28.64 to –7.30 
 
298 
–14.35  98.25 
–25.63 to –3.07 
 
 
6.668 
 (–6.877, 20.213) 
p=0.334 
Asthma symptoms    
Symptoms score (N)* 
    Mean change  SD  
    95% CI 
184 
0.05  0.41 
–0.02 to 0.11 
217 
0.04  0.26 
0.01 to 0.08 
 
–0.036 
 (–0.109, 0.037) 
    P-value 
% of days without 
symptoms (N)* 
    Mean change  SD  
    95% CI 
    P-value 
184 
–4.24  29.72 
–8.97 to 0.49 
217 
–3.42  22.07 
–6.52 to –0.32 
p=0.329 
 
4.065 
 (–1.351, 9.480) 
p=0.141 
Use of rescue medication    
Rescue medication, 
puffs/day (N)* 
    Mean change  SD  
    95% CI 
174 
0.22  0.71 
0.10 to 0.34 
212 
0.08  0.50 
0.01 to 0.15 
 
–0.172 
 (–0.306, –0.038) 
    P-value 
% of days without rescue 
(N)* 
    Mean change  SD  
    95% CI 
    P-value 
174 
–9.55  28.57 
–14.28 to –4.81 
212 
–3.15  22.57 
–6.37 to 0.07 
p=0.012 
 
8.313 
 (2.740, 13.886) 
p=0.004 
Asthma control    
ACQ, score (N) 
    Mean change  SD  
    95% CI 
    P-value 
230 
0.00  0.76  
–0.10 to 0.10 
284 
–0.03  0.63 
–0.10 to 0.05 
 
–0.062  
(–0.168, 0.045) 
p=0.254 
% of days of asthma 
control (N)* 
    Mean change  SD  
    95% CI 
    P-value 
173 
–7.11  30.55  
–12.20 to –2.03 
210 
–5.55  26.26 
–9.33 to –1.77 
  
4410  
 (1.853, 10.673) 
p=0.167 
*in the 2 weeks preceding the medical visit. 
**measured at sites. 
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Data are expressed as changes from baseline to the end of the 6-week follow-up 
SMART therapy (week 58). All measurements were performed pre-bronchodilator 
unless otherwise indicated.      N = number of patients; ACQ = Asthma Control Questionnaire. 
 
 
 
 
 
 
 
40 
 
 
Figure 1. Study design. 
 
 
Flow Chart 
 
 
 
 
 
Figure 2. Kaplan-Meier plots for the time to treatment failure with the first (left  graph) and 
second (right graph) sensitivity analyses (ITT population). All patients who dropped out of the 
study were included as treatment failures. First analysis: Reasons for drop-out were “Patient’s 
consent withdrawn” or “Other.” Second analysis: Any reason for drop-out. 
 
41 
Figure 3. Kaplan-Meier plot for the time to drop-out (ITT population). 
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